Barclays analyst Jack Meehan maintained a Buy rating on IQVIA Holdings Inc (IQV) yesterday and set a price target of $171. The company’s shares closed yesterday at $136.29.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 6.9% and a 62.1% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and Syneos Health Inc.
Currently, the analyst consensus on IQVIA Holdings Inc is a Strong Buy with an average price target of $159.71, a 17.2% upside from current levels. In a report issued on April 11, Credit Suisse also maintained a Buy rating on the stock with a $159 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $146.10 and a one-year low of $91.57. Currently, IQVIA Holdings Inc has an average volume of 1.26M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IQVIA Holdings, Inc. operates as a biotechnology company. It engages in healthcare development in the provision of professional services, information technology, and partnering solutions to the pharmaceutical services and healthcare industries. The company was founded by Dennis Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
